- Home
- SUIG vs AARD Comparison
SUIG vs AARD Comparison
Compare SUIG & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUIG
- AARD
- Stock Information
- Founded
- SUIG 2006
- AARD 2017
- Country
- SUIG United States
- AARD United States
- Employees
- SUIG N/A
- AARD N/A
- Industry
- SUIG Finance Companies
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- SUIG Finance
- AARD Health Care
- Exchange
- SUIG Nasdaq
- AARD Nasdaq
- Market Cap
- SUIG 250.4M
- AARD 277.9M
- IPO Year
- SUIG N/A
- AARD 2025
- Fundamental
- Price
- SUIG $3.30
- AARD $12.00
- Analyst Decision
- SUIG Strong Buy
- AARD Strong Buy
- Analyst Count
- SUIG 2
- AARD 7
- Target Price
- SUIG $5.75
- AARD $31.43
- AVG Volume (30 Days)
- SUIG 1.6M
- AARD 168.1K
- Earning Date
- SUIG 11-11-2025
- AARD 11-14-2025
- Dividend Yield
- SUIG N/A
- AARD N/A
- EPS Growth
- SUIG 619.34
- AARD N/A
- EPS
- SUIG 0.24
- AARD N/A
- Revenue
- SUIG $3,305,884.00
- AARD N/A
- Revenue This Year
- SUIG N/A
- AARD N/A
- Revenue Next Year
- SUIG N/A
- AARD N/A
- P/E Ratio
- SUIG $13.92
- AARD N/A
- Revenue Growth
- SUIG 1.77
- AARD N/A
- 52 Week Low
- SUIG $1.13
- AARD $4.88
- 52 Week High
- SUIG $8.66
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- SUIG N/A
- AARD 45.02
- Support Level
- SUIG N/A
- AARD $10.57
- Resistance Level
- SUIG N/A
- AARD $17.94
- Average True Range (ATR)
- SUIG 0.00
- AARD 1.03
- MACD
- SUIG 0.00
- AARD -0.50
- Stochastic Oscillator
- SUIG 0.00
- AARD 21.49
About SUIG Sui Group Holdings Limited Common Stock
Sui Group Holdings Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.